Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to -$187.2 million.

  • Dare Bioscience's Retained Earnings fell 1027.51% to -$187.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$187.2 million, marking a year-over-year decrease of 1027.51%. This contributed to the annual value of -$175.3 million for FY2024, which is 236.73% down from last year.
  • Dare Bioscience's Retained Earnings amounted to -$187.2 million in Q3 2025, which was down 1027.51% from -$183.7 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Retained Earnings registered a high of -$78.8 million during Q1 2021, and its lowest value of -$187.2 million during Q3 2025.
  • In the last 5 years, Dare Bioscience's Retained Earnings had a median value of -$157.9 million in 2023 and averaged -$145.5 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 6314.7% in 2021, then crashed by 95.51% in 2025.
  • Quarter analysis of 5 years shows Dare Bioscience's Retained Earnings stood at -$110.1 million in 2021, then decreased by 28.1% to -$141.1 million in 2022, then decreased by 21.38% to -$171.2 million in 2023, then decreased by 2.37% to -$175.3 million in 2024, then dropped by 6.82% to -$187.2 million in 2025.
  • Its last three reported values are -$187.2 million in Q3 2025, -$183.7 million for Q2 2025, and -$179.7 million during Q1 2025.